Management of proctitis in ulcerative colitis and the place of biological therapies

References

• Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc [Internet]. 2019;94:1357–1373. doi: 10.1016/j.mayocp.2019.01.018
   PubMed Web of Science ®Google Scholar
• Adams SM, Close ED, Shreenath AP. Ulcerative colitis: rapid evidence review. Am Fam Physician. 2022;105(4):406–411.
   PubMed Web of Science ®Google Scholar
• Segal JP, Jean-Frédéric LeBlanc A, Hart AL. Ulcerative colitis: an update. Clin Med J R Coll Physicians London. 2021;21(2):135–139. doi: 10.7861/clinmed.2021-0080
   Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi: 10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Gaweł K, Dąbkowski K, Zawada I, et al. Progression risk factors of ulcerative proctitis. Scand J Gastroenterol. 2022;57(12):1406–1411. doi: 10.1080/00365521.2022.2094726
   PubMed Web of Science ®Google Scholar
• Kiss LS, Lakatos PL. Natural history of ulcerative colitis: current knowledge. Curr Drug Targets. 2011;12(10):1390–1395. doi: 10.2174/138945011796818117
   PubMed Web of Science ®Google Scholar
• Attauabi M, Madsen GR, Bendtsen F, et al. P238 Symptom burden and indolent disease in newly diagnosed patients with ulcerative colitis and Crohn’s disease–a Copenhagen IBD inception cohort study. J Crohn’s Colitis [Internet]. 2022;16:i285–i287. doi: 10.1093/ecco-jcc/jjab232.365
   Google Scholar
• Sninsky JA, Barnes EL, Zhang X, et al. Urgency and its association with quality of life and clinical outcomes in patients with ulcerative colitis. Am J Gastroenterol. 2022;117(5):769–776. doi: 10.14309/ajg.0000000000001685
   PubMed Web of Science ®Google Scholar
• Caron B, Abreu MT, Siegel CA, et al. IOIBD recommendations for clinical trials in ulcerative proctitis: the PROCTRIAL consensus. Clin Gastroenterol Hepatol. 2022;20(11):2619–2627.e1. doi: 10.1016/j.cgh.2022.02.032
   PubMed Web of Science ®Google Scholar
• Michalopoulos G, Karmiris K. When disease extent is not always a key parameter: management of refractory ulcerative proctitis. Curr Res Pharmacol Drug Discov [Internet]. 2022;3:100071. doi: 10.1016/j.crphar.2021.100071
   PubMedGoogle Scholar
• Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort – An Epi-IBD Study. J Crohns Colitis. 2019;13(2):198–208. doi: 10.1093/ecco-jcc/jjy154
   PubMed Web of Science ®Google Scholar
• Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis [Internet]. Disease-A-Month. 2019;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12(7):543–550. doi: 10.1097/01.MIB.0000225339.91484.fc
   PubMed Web of Science ®Google Scholar
• Burisch J, Ungaro R, Vind I, et al. Proximal disease extension in patients with limited ulcerative colitis: a Danish population based inception cohort. J Crohn‘s Colitis. 2017;11(10):1200–1204. doi: 10.1093/ecco-jcc/jjx066
   Google Scholar
• Huguet JM, Ferrer-Barceló L, Suárez P, et al. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? Scand J Gastroenterol. [Internet]. 2018;53:1286–1290. doi: 10.1080/00365521.2018.1524026
   PubMed Web of Science ®Google Scholar
• Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49(2):177–183. doi: 10.3109/00365521.2013.867360
   PubMed Web of Science ®Google Scholar
• Kato S, Ishibashi A, Kani K, et al. Optimized management of ulcerative proctitis: when and how to use mesalazine suppository. Digestion. 2018;97(1):59–63. doi: 10.1159/000484224
   PubMed Web of Science ®Google Scholar
• Dubois E, Moens A, Geelen R, et al. Long-term outcomes of patients with ulcerative proctitis: analysis from a large referral centre cohort. United Eur Gastroenterol J. 2020;8(8):933–941. doi: 10.1177/2050640620941345
   PubMed Web of Science ®Google Scholar
• Raine T, Verstockt B, Kopylov U, et al. ECCO topical review: refractory inflammatory bowel disease. J Crohns Colitis. 2021;15(10):1605–1620. doi: 10.1093/ecco-jcc/jjab112
   PubMed Web of Science ®Google Scholar
• Hochart A, Gower-Rousseau C, Sarter H, et al. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut. 2017;66(11):1912–1917. doi: 10.1136/gutjnl-2016-311970
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794.e4. doi: 10.1053/j.gastro.2011.01.055
   PubMed Web of Science ®Google Scholar
• Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423–432. doi: 10.1136/gutjnl-2012-303864
   PubMed Web of Science ®Google Scholar
• van den Heuvel Tra, Jeuring SFG, Zeegers MP, et al. A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch ibdsl cohort – can diagnostic factors explain the increase in IBD incidence? J Crohns Colitis. 2017;11(10):1169–1179. doi: 10.1093/ecco-jcc/jjx055
   PubMed Web of Science ®Google Scholar
• Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol. 2000;95(2):469–473. doi: 10.1111/j.1572-0241.2000.t01-1-01770.x
   PubMed Web of Science ®Google Scholar
• Ayres RC, Gillen CD, Walmsley RS, et al. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol. 1996;8(6):555–558. doi: 10.1097/00042737-199606000-00011
   PubMed Web of Science ®Google Scholar
• Anzai H, Hata K, Kishikawa J, et al. Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. null Dis. 2016;18(3):O97–O102. doi: 10.1111/codi.13237
   Google Scholar
• Walsh E, Chah YW, Chin SM, et al. Clinical predictors and natural history of disease extension in patients with ulcerative proctitis. Inflamm Bowel Dis. 2017;23(11):2035–2041. doi: 10.1097/MIB.0000000000001214
   PubMed Web of Science ®Google Scholar
• Parian A, Limketkai B, Koh J, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut. 2017;66(8):1390–1397. doi: 10.1136/gutjnl-2016-311550
   PubMed Web of Science ®Google Scholar
• Safroneeva E, Vavricka S, Fournier N, et al. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Aliment Pharmacol Ther. 2015;42(5):540–548. doi: 10.1111/apt.13307
   PubMed Web of Science ®Google Scholar
• Frias Gomes Cg D, De Almeida ASR, Mendes CCL, et al. Histological inflammation in the endoscopically uninflamed mucosa is associated with worse outcomes in limited ulcerative colitis. Inflamm Bowel Dis. 2022;28(3):350–357. doi: 10.1093/ibd/izab069
   PubMed Web of Science ®Google Scholar
• Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13–20. doi: 10.1053/gast.2001.20912
   PubMed Web of Science ®Google Scholar
• Anzai H, Hata K, Kishikawa J, et al. Appendiceal orifice inflammation is associated with proximal extension of disease in patients with ulcerative colitis. Null Dis Off J Assoc Coloproctology Gt Null Irel. 2016;18(8):O278–82. doi: 10.1111/codi.13435
   Google Scholar
• Byeon J-S, Yang S-K, Myung S-J, et al. Clinical course of distal ulcerative colitis in relation to appendiceal orifice inflammation status. Inflamm Bowel Dis. 2005;11(4):366–371. doi: 10.1097/01.MIB.0000164018.06538.6e
   PubMed Web of Science ®Google Scholar
• Kuk KW, Gwon JY, Soh JS, et al. Clinical significance and long-term prognosis of ulcerative colitis patients with appendiceal orifice inflammation. BMC Gastroenterol. [Internet]. 2022;22(1):1–8. doi: 10.1186/s12876-022-02627-w
   PubMed Web of Science ®Google Scholar
• Fdez-Morera JL, Rodrigo L, López-Vázquez A, et al. MHC class I chain-related gene a transmembrane polymorphism modulates the extension of ulcerative colitis. Hum Immunol. 2003;64(8):816–822. doi: 10.1016/S0198-8859(03)00121-6
   PubMed Web of Science ®Google Scholar
• Argmann C, Tokuyama M, Ungaro RC, et al. Molecular characterization of limited ulcerative colitis reveals novel biology and predictors of disease extension. Gastroenterology. 2021;161(6):1953–1968.e15. doi: 10.1053/j.gastro.2021.08.053
   PubMed Web of Science ®Google Scholar
• Walker DG, Williams HRT, Kane SP, et al. Differences in inflammatory bowel disease phenotype between south asians and northern Europeans living in north west London, UK. Am J Gastroenterol [Internet]. 2011;106:1281–1289. doi: 10.1038/ajg.2011.85
   PubMed Web of Science ®Google Scholar
• Aruljothy A, Singh S, Narula N, et al. Systematic review with meta-analysis: medical therapies for treatment of ulcerative proctitis. Aliment Pharmacol Ther. 2023;58(8):740–762. doi: 10.1111/apt.17666
   PubMed Web of Science ®Google Scholar
• Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000;47(3):410–414. doi: 10.1136/gut.47.3.410
   PubMed Web of Science ®Google Scholar
• Campieri M, Corbelli C, Gionchetti P, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci. 1992;37(12):1890–1897. doi: 10.1007/BF01308084
   PubMed Web of Science ®Google Scholar
• Wilding IR, Kenyon CJ, Chauhan S, et al. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther. 1995;9(2):161–166. doi: 10.1111/j.1365-2036.1995.tb00365.x
   PubMed Web of Science ®Google Scholar
• Brown J, Haines S, Wilding IR. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther. 1997;11(4):685–691. doi: 10.1046/j.1365-2036.1997.00193.x
   PubMed Web of Science ®Google Scholar
• Van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther. 1996;10(3):327–332. doi: 10.1111/j.0953-0673.1996.00327.x
   PubMed Web of Science ®Google Scholar
• Brunner M, Vogelsang H, Greinwald R, et al. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2005;22(5):463–470. doi: 10.1111/j.1365-2036.2005.02571.x
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;CD004115. doi: 10.1002/14651858.CD004115.pub2
   Google Scholar
• Kruis W, Siegmund B, Lesniakowski K, et al. Novel budesonide suppository and standard budesonide rectal foam induce high rates of clinical remission and mucosal healing in active ulcerative proctitis: a randomised, controlled, non-inferiority trial. J Crohns Colitis. 2022;16(11):1714–1724. doi: 10.1093/ecco-jcc/jjac081
   PubMed Web of Science ®Google Scholar
• Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10(6):731–736. doi: 10.1097/00054725-200411000-00006
   PubMed Web of Science ®Google Scholar
• Cuomo A, Sgambato D, D’Auria MV, et al. Multi matrix system mesalazine plus rectal mesalazine in the treatment of mild to moderately active ulcerative proctitis. Dig Dis. 2018;36(2):130–135. doi: 10.1159/000485614
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis. Aliment Pharmacol Ther. 1995;9(3):293–300. doi: 10.1111/j.1365-2036.1995.tb00384.x
   PubMed Web of Science ®Google Scholar
• Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56(2):513–522. doi: 10.1007/s10620-010-1334-y
   PubMed Web of Science ®Google Scholar
• Andus T, Kocjan A, Müser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16(11):1947–1956. doi: 10.1002/ibd.21258
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–1276. doi: 10.1111/j.1572-0241.2000.01940.x
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo-controlled study. Aliment Pharmacol Ther. 2013;38(3):264–273. doi: 10.1111/apt.12362
   PubMed Web of Science ®Google Scholar
• Varum F, Thorne H, Bravo R, et al. Targeted colonic release formulations of mesalazine – a clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis. Int J Pharm. 2022;625:122055. doi: 10.1016/j.ijpharm.2022.122055
   PubMedGoogle Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–97. doi: 10.1007/BF02236902
   PubMed Web of Science ®Google Scholar
• Hebden JM, Blackshaw PE, Perkins AC, et al. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2000;14(2):155–161. doi: 10.1046/j.1365-2036.2000.00697.x
   PubMed Web of Science ®Google Scholar
• Boyle M, Ting A, Cury DB, et al. Adherence to rectal mesalamine in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(12):2873–2878. doi: 10.1097/MIB.0000000000000562
   PubMed Web of Science ®Google Scholar
• Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs. oral plus topical treatment. Aliment Pharmacol Ther. 1999;13(11):1413–1417. doi: 10.1046/j.1365-2036.1999.00642.x
   PubMed Web of Science ®Google Scholar
• Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–1871.
   PubMed Web of Science ®Google Scholar
• Campieri M, Cottone M, Miglio F, et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther. 1998;12(4):361–366. doi: 10.1046/j.1365-2036.1998.00299.x
   PubMed Web of Science ®Google Scholar
• Biancone L, Gionchetti P, Blanco GDV, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2007;39(4):329–337. doi: 10.1016/j.dld.2007.01.012
   Google Scholar
• Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015;148(4):740–750.e2. doi: 10.1053/j.gastro.2015.01.037
   PubMed Web of Science ®Google Scholar
• Naganuma M, Aoyama N, Suzuki Y, et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. J Crohns Colitis. 2016;10(7):828–836. doi: 10.1093/ecco-jcc/jjv208
   PubMed Web of Science ®Google Scholar
• Naganuma M, Aoyama N, Tada T, et al. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol. 2018;53(4):494–506. doi: 10.1007/s00535-017-1376-4
   PubMed Web of Science ®Google Scholar
• Kruis W, Neshta V, Pesegova M, et al. Budesonide suppositories are effective and safe for treating acute ulcerative proctitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(1):98–106.e4. doi: 10.1016/j.cgh.2018.04.027
   PubMed Web of Science ®Google Scholar
• Frei P, Biedermann L, Manser CN, et al. Topical therapies in inflammatory bowel disease. Digestion. 2012;86(Suppl. 1):36–44. doi: 10.1159/000341947
   PubMedGoogle Scholar
• Lawrance IC, Copeland T-S. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008;28(10):1214–1220. doi: 10.1111/j.1365-2036.2008.03841.x
   PubMed Web of Science ®Google Scholar
• van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009;15(2):193–198. doi: 10.1002/ibd.20644
   PubMed Web of Science ®Google Scholar
• Lie MRKL, Kreijne JE, Dijkstra G, et al. No superiority of tacrolimus suppositories vs beclomethasone suppositories in a randomized trial of patients with refractory ulcerative proctitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;18(8):1777–1784.e2. doi: 10.1016/j.cgh.2019.09.049
   PubMed Web of Science ®Google Scholar
• Connell AM, Lennard-Jones JE, Misiewicz JJ, et al. Comparison of acetarsol and prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Lancet. 1965;1(7379):238. doi: 10.1016/S0140-6736(65)91523-0
   PubMed Web of Science ®Google Scholar
• Argyriou K, Samuel S, Moran GW. Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience. Eur J Gastroenterol Hepatol. 2019;31(2):183–186. doi: 10.1097/MEG.0000000000001326
   PubMed Web of Science ®Google Scholar
• Raja SS, Bryant RV, Costello SP, et al. Systematic review of therapies for refractory ulcerative proctitis. J Gastroenterol Hepatol. [Internet]. 2023;38(4):496–509. doi: 10.1111/jgh.16111
   PubMed Web of Science ®Google Scholar
• Mallet AL, Bouguen G, Conroy G, et al. Azathioprine for refractory ulcerative proctitis: a retrospective multicenter study. Dig Liver Dis [Internet]. 2017;49:280–285. doi: 10.1016/j.dld.2016.12.001
   PubMedGoogle Scholar
• Bolin TD, Wong S, Crouch R, et al. Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol. 2009;104(10):2476–2482. doi: 10.1038/ajg.2009.388
   PubMed Web of Science ®Google Scholar
• Bageacu S, Coatmeur O, Lemaitre JP, et al. Appendicectomy as a potential therapy for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2011;34(2):257–258. doi: 10.1111/j.1365-2036.2011.04705.x
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi: 10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–211. doi: 10.1002/ibd.21697
   PubMed Web of Science ®Google Scholar
• Moss AC, Farrell RJ. Infliximab for induction and maintenance therapy for ulcerative colitis. Gastroenterology. 2006;131(5):1649–1651. doi: 10.1053/j.gastro.2006.09.039
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85. doi: 10.1053/j.gastro.2013.05.048
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787. doi: 10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Bouguen G, Roblin X, Bourreille A, et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010;31(11):1178–1185. doi: 10.1111/j.1365-2036.2010.04293.x
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Amiot A, Bouguen G, et al. Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis. Clin Gastroenterol Hepatol. 2020;18(3):620–627.e1. doi: 10.1016/j.cgh.2019.05.060
   PubMed Web of Science ®Google Scholar
• Uzzan M, Nachury M, Nuzzo A, et al. Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID. J Crohn’s Coli. 2023;18(3):424–430. doi: 10.1093/ecco-jcc/jjad169
   Web of Science ®Google Scholar
• Lemmens P, Louis E, Van Moerkercke W, et al. Outcome of biological therapies and small molecules in ulcerative proctitis: a Belgian multicenter cohort study. Clin Gastroenterol Hepatol [Internet]. 2024;22(1):154–163.e3. doi: 10.1016/j.cgh.2023.06.023
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159–1171. doi: 10.1016/S0140-6736(23)00061-2
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi: 10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• López-Sanromán A, Esplugues JV, Domènech E. Farmacología y seguridad de tofacitinib en colitis ulcerosa. Gastroenterología y Hepatología. 2021;44(1):39–48. doi: 10.1016/j.gastrohep.2020.04.012
   PubMed Web of Science ®Google Scholar
• Singh A, Mahajan R, Midha V, et al. Effectiveness of tofacitinib in ulcerative proctitis compared to left sided colitis and pancolitis. Dig Dis Sci. [Internet]. 2024;69(4):1389–1402. doi: 10.1007/s10620-024-08276-1
   PubMed Web of Science ®Google Scholar
• Caron B, Sandborn WJ, Schreiber S, et al. Drug development for ulcerative proctitis: current concepts. Gut. 2021;70(7):1203–1209. doi: 10.1136/gutjnl-2021-324108
   PubMed Web of Science ®Google Scholar
• Truelove SC. Suppository treatment of haemorrhagic proctitis. Br Med J. 1959;1(5127):955–958. doi: 10.1136/bmj.1.5127.955
   PubMedGoogle Scholar
• Armuzzi A, Danese S, Barreiro-de Acosta M, et al. P931 burden of disease among ulcerative colitis patients with isolated proctitis in the United States and Europe. J Crohn’s Colitis. 2024;18(Supplement_1):i1694–i1696. doi: 10.1093/ecco-jcc/jjad212.1061
   Google Scholar
• Pineton de Chambrun G, Tassy B, Kollen L, et al. Refractory ulcerative proctitis: how to treat it? best pract res clin gastroenterol [Internet]. Best Pract Res Clin Gastroenterol. 2018;32–33:49–57. Available from: https://www.sciencedirect.com/science/article/pii/S1521691818300258
   PubMed Web of Science ®Google Scholar
• Nigam GB, Limdi JK, Bate S, et al. Fecal urgency in ulcerative colitis: impact on quality of life and psychological well-being in active and inactive disease states. Clin Gastroenterol Hepatol. 2024. doi: 10.1016/j.cgh.2023.12.019
   Google Scholar
• Dubinsky MC, Irving PM, Panaccione R, et al. Incorporating patient experience into drug development for ulcerative colitis: development of the urgency numeric rating scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient-Reported Outcomes. 2022;6(1):31. doi: 10.1186/s41687-022-00439-w
   PubMedGoogle Scholar
• Dubinsky MC, Newton L, Delbecque L, et al. Exploring disease remission and bowel urgency severity among adults with moderate to severe ulcerative colitis: a qualitative study. Patient Relat Outcome Meas. 2022;13:287–300. doi: 10.2147/PROM.S378759
   PubMed Web of Science ®Google Scholar